Type 1 Diabetes – Landscape & Forecast – Disease Landscape & Forecast

The next 10 years will be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to increase. Therapies in the late-phase pipeline represent drug classes already on the market for type 2 diabetes (e.g., SGLT-2 inhibitors), but a few early-phase agents (e.g., VX-880) offer a novel mechanism of action. The emphasis has shifted on the types of therapies in development for T1D; interest in pancreatic beta-cell replacement therapies and CD3 antigen inhibitors is significant. The availability of biosimilar insulins is also likely to have a sizable effect on the T1D therapy market throughout the G7, resulting in an intricate interplay of physician and payer attitudes toward this treatment option.

QUESTIONS ANSWERED

  • What are the drivers and constraints in the T1D market, and how will the market evolve over the forecast period?
  • How are biosimilar insulins being adopted in the markets under study?
  • What impact will the increasing use of insulin pumps have on market dynamics?
  • How will endocrinologists differentiate between the emerging therapies, and which agents will enjoy the most clinical and commercial success in an increasingly stringent regulatory and cost-sensitive environment?
  • How will ultra-rapid insulins, such as Novo Nordisk’s Fiasp and Eli Lilly’s Lyumjev, be incorporated into treatment in the major markets?

CONTENT HIGHLIGHTS

Geographies: United States, EU5, Japan.

Primary research: 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Prevalence of T1D by country with population-specific diagnosed and drug-treatment rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key T1D therapies through 2031, segmented by brands / generics and epidemiological subpopulations.

Emerging therapies: Phase III/PR: 5 drugs; coverage of select preclinical, Phase I, and Phase II products.

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Type 1 Diabetes - Landscape & Forecast - Disease Landscape & Forecast
    • Key findings
      • Type 1 diabetes key findings - July 2022
    • Key updates
      • Q4 2022
        • December 2022
        • November 2022
        • October 2022
      • Q3 2022
        • September 2022
        • August 2022
      • Q2 2022
        • May 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
    • Market outlook
      • Key findings
        • Market share of drug classes for type 1 diabetes: 2021
        • Market share of drug classes for type 1 diabetes: 2031
        • Type 1 diabetes SWOT analysis
      • Market drivers and constraints
        • What factors are driving the market for type 1 diabetes?
        • What factors are constraining the market for type 1 diabetes?
        • Market sales of type 1 diabetes drug classes in the major markets: 2021-2031
        • Patient share of type 1 diabetes drug classes in the major markets: 2021-2031
      • Drug-class specific trends
        • Long-acting insulins
        • Patient share of long-acting insulins in type 1 diabetes in the United States: 2021-2031
        • Patient share of long-acting insulins in type 1 diabetes in Europe: 2021-2031
        • Patient share of long-acting insulins in type 1 diabetes in Japan: 2021-2031
        • Rapid-acting insulins
        • Patient share of rapid-acting insulins in type 1 diabetes in the United States: 2021-2031
        • Patient share of rapid-acting insulins in type 1 diabetes in Europe: 2021-2031
        • Patient share of rapid-acting insulins in type 1 diabetes in Japan: 2021-2031
        • Ultra-rapid-acting insulins
        • Patient share of ultra-rapid-acting insulins in type 1 diabetes in major markets: 2021-2031
        • Other insulins
        • Patient share of other insulins in type 1 diabetes in major markets: 2021-2031
        • Patient share of SGLT inhibitors in type 1 diabetes in major markets: 2021-2031
        • Patient share of immunotherapy in type 1 diabetes (newly-diagnosed patients) in major markets: 2021-2031
        • Market sales of immunotherapy in type 1 diabetes (newly-diagnosed patients) in major markets: 2021-2031
    • Forecast
      • Market forecast assumptions
      • Market forecast dashboard
    • Etiology and pathophysiology
      • Disease overview
        • Etiology
          • Risk factors for type 1 diabetes
        • Pathophysiology
          • Type 1 diabetes: how the disease might arise
        • Natural history
          • Key pathways and drug targets
            • Summary of type 1 diabetes drug targets
        • Epidemiology overview
          • Key findings
            • Epidemiology populations
              • Disease definition
              • Methods
              • Sources used for diagnosed prevalence estimates of type 1 diabetes
              • Diagnosed prevalent cases of type 1 diabetes: 2021-2031 (thousands)
              • Drug-treated prevalent cases of type 1 diabetes: 2021-2031 (thousands)
          • Current treatment
            • Key findings
              • Treatment goals
                • Key endpoints used in clinical trials for type 1 diabetes
              • Key current therapies
                • Overview
                • Mechanism of action of key current drugs used for type 1 diabetes
                • Current treatments used for type 1 diabetes
                • Advantages and disadvantages of Glargine U100
                • Advantages and disadvantages of detemir
                • Advantages and disadvantages of degludec
                • Advantages and disadvantages of glargine U300
                • Expert insight: long-acting insulins
                • Advantages and disadvantages of aspart
                • Advantages and disadvantages of glulisine
                • Advantages and disadvantages of lispro
                • Advantages and disadvantages of technosphere
                • Ongoing clinical development of technosphere
                • Expert insight: rapid-acting insulins
                • Advantages and disadvantages of ultra-rapid aspart
                • Advantages and disadvantages of ultra-rapid lispro
                • Expert insight: ultra-rapid-acting insulins
                • Advantages and disadvantages of premixed insulins
                • Expert insight: premixed insulins
                • Advantages and disadvantages of regular insulin
                • Advantages and disadvantages of NPH insulin
                • Expert insight: short- and intermediate-acting insulins
                • Advantages and disadvantages of dapagliflozin
                • Advantages and disadvantages of ipragliflozin
                • Expert insight: SGLT inhibitors
                • Advantages and disadvantages of pramlintide
              • Medical practice
                • Overview
                • Factors influencing drug selection in type 1 diabetes
                • Generalized treatment decision tree for type 1 diabetes: major markets
            • Unmet need overview
              • Current and future attainment of unmet needs in type 1 diabetes
              • Top unmet needs in type 1 diabetes: current and future attainment
              • Expert insight: unmet need in type 1 diabetes
            • Drug pipeline
              • Pipeline
              • Regulatory Milestones
              • Indication Comparison
            • Emerging therapies
              • Key findings
                • Key emerging therapies
                  • Key therapies in development for type 1 diabetes
                  • Estimated launch dates of key emerging therapies for the treatment of type 1 diabetes
                  • Teplizumab profile
                  • Key ongoing clinical trials of teplizumab for the treatment of type 1 diabetes
                  • Analysis of the clinical development program for teplizumab
                  • Expectations for launch and sales opportunity of teplizumab in type 1 diabetes
                  • Expert insight: teplizumab
                  • Key results from select clinical trials investigating ladarixin for the treatment of type 1 diabetes
                  • Key ongoing clinical trials of ladarixin for the treatment of type 1 diabetes
                  • Analysis of the clinical development program for ladarixin
                  • Expectations for launch and sales opportunity of ladarixin in type 1 diabetes
                  • Key results from select clinical trials investigating Diamyd for the treatment of type 1 diabetes
                  • Key ongoing clinical trials of Diamyd for the treatment of type 1 diabetes
                  • Analysis of the clinical development program for Diamyd
                  • Expectations for launch and sales opportunity of Diamyd in type 1 diabetes
                  • Key ongoing clinical trials of insulin icodec for the treatment of type 1 diabetes
                  • Analysis of the clinical development program for insulin icodec
                  • Expectations for launch and sales opportunity of insulin icodec in type 1 diabetes
                  • Key ongoing clinical trials of LY3209590 for the treatment of type 1 diabetes
                  • Analysis of the clinical development program for LY3209590
                  • Expectations for launch and sales opportunity of LY3209590 in type 1 diabetes
                  • Sotagliflozin profile
                  • Analysis of the clinical development program for sotagliflozin
                  • Expectations for launch and sales opportunity of sotagliflozin in type 1 diabetes
                • Early-phase pipeline analysis
                  • Select compounds in Phase II development for type 1 diabetes
              • Access & reimbursement overview
                • Region-specific reimbursement practices
                  • Key market access considerations in type 1 diabetes: United States
                  • General reimbursement environment: United States
                  • Key market access considerations in type 1 diabetes: EU5
                  • General reimbursement environment: EU5
                  • Key market access considerations in type 1 diabetes: Japan
                  • General reimbursement environment: Japan
              • Appendix
                • Abbreviations
                • Type 1 diabetes bibliography

            Login to access report